Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model
Author(s) -
Lander Foquet,
Cornelus C. Hermsen,
Lieven Verhoye,
GeertJan van Gemert,
Riccardo Cortese,
Alfredo Nicosia,
Robert W. Sauerwein,
Geert LerouxRoels,
Philip Meuleman
Publication year - 2015
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkv019
Subject(s) - plasmodium falciparum , biology , monoclonal antibody , scavenger receptor , cd81 , virology , malaria , antibody , immunology , in vivo , hepatocyte , in vitro , hepatitis c virus , virus , lipoprotein , biochemistry , cholesterol , microbiology and biotechnology
Plasmodium falciparum sporozoites, deposited in the skin by infected Anopheles mosquitoes taking a blood meal, cross the endothelium of skin capillaries and travel to the liver where they traverse Kupffer cells and hepatocytes to finally invade a small number of the latter. In hepatocytes, sporozoites replicate, differentiate and give rise to large numbers of merozoites that are released into the bloodstream where they invade red blood cells, thus initiating the symptomatic blood stage. Using in vitro systems and rodent models, it has been shown that the hepatocyte receptors CD81 and scavenger receptor type B class I (SR-BI) play a pivotal role during sporozoite invasion. We wanted to evaluate whether these two entry factors are genuine drug targets for the prevention of P. falciparum infection in humans.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom